DocuSign DOCU 深 滬
等待開盤 01-30 09:30:00 美东时间
53.78
-2.435
-4.33%
華盛通- 最 高54.53
- 今 開54.46
- 成交量 586.34万股
- 最 低 51.90
- 昨 收 56.215
- 總市值 107.56亿
- 52周最高 94.67
- 市盈率 靜 10.59
- 換手率 2.93%
- 52周最低 51.90
- 委 比 66.67%
- 總股本 2.00亿
- 歷史最高 314.76
- 量 比 1.57
- 振 幅 4.68%
- 歷史最低 35.06
- 每 手 1
- 風險率 8.67%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Trip.com, Regencell Bioscience, And Atlassian Are Among Top 10 Large Cap Losers Last Week (Jan. 12-Jan. 16): Are the Others in Your Portfolio?
Regencell led last week's large-cap losers as Figma, Atlassian and Trip.com slid on downgrades, probes and broader tech weakness.
01-19 01:31
DocuSign Stock Sinks despite AI Push to Kill Contract Paperwork
DocuSign’s ($DOCU) shares tumbled on Tuesday afternoon despite the electronic s...
01-14 02:15
Docusign's New AI Translates Legalese and Does Your Contract Busywork
New eSignature features bring clarity for signers and efficiency gains for businesses SAN FRANCISCO, Jan. 13, 2026 /PRNewswire/ -- Docusign (NASDAQ: DOCU) today announced new AI-powered eSig...
01-14 00:00
DocuSign Stock Jumps as Wall Street Warms Up
DocuSign ( ($DOCU) ) has risen by 8.49%. Read on to learn why. DocuSign shares ...
01-10 22:01
美股大行评级 | 潜在涨幅36.7%！LMRI获多家大行首予超配评级； 瑞银下调甲骨文目标价从325美元至280美元
今日重点评级关注：HC Wainwright & Co.：维持Assertio Holdings"买入"评级，目标价从3美元升至35美元；HC Wainwright & Co.：维持万达生物制药"买入"评级，目标价从20美元升至22美元
01-06 17:52
RBC Capital Maintains Sector Perform on Docusign, Lowers Price Target to $70
RBC Capital analyst Rishi Jaluria maintains Docusign (NASDAQ:DOCU) with a Sector Perform and lowers the price target from $95 to $70.
01-05 23:01
韦德布什分析师警告：这12家科技公司可能成为AI时代的输家
随着人工智能改变经济格局并创造新的赢家，那些不能足够快地采用这项技术的公司将面临被淘汰的风险。 近日，韦德布什证券（Wedbush Securities）的分析...
2025-12-29 16:56
美股大行评级 | 德银首予Coinbase"买入"评级，目标价340美元；AERO获多家机构首予超配评级；大摩维持苹果"超配"评级，目标价升至315美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从9美元升至10美元；摩根大通：上调Recursion Pharmaceuticals评级至"超配"，目标价从10美元升至11美元
2025-12-18 10:54
Docusign possible of reaching, surpassing 10% ARR growth, Needham says
Docusign (DOCU) is capable of hitting — and surpassing — 10% growth in annual recurring revenue, investment firm Needham said, after a recent meeting with company management. “The change in billings ...
2025-12-18 03:30
BTIG Initiates Coverage On Docusign with Buy Rating, Announces Price Target of $88
BTIG analyst Allan Verkhovski initiates coverage on Docusign (NASDAQ:DOCU) with a Buy rating and announces Price Target of $88.
2025-12-17 19:18
